Daily subq vs weekly IM:
the half-life argument that every TRT clinic should be making.

Ask any man who's been on weekly intramuscular testosterone replacement for more than six months, and he'll tell you the same thing: it works, but it doesn't quite work. Energy is strong for two days. Sleep is great for two more. Then by Friday or Saturday, something fades. Libido softens. Mood blurs. He starts looking at the calendar wondering if Monday is too far away.

That feeling isn't him. That feeling is the serum testosterone curve doing what the literature says it does — and what most TRT clinics still haven't bothered to fix.

The half-life of the molecule, not the protocol

Testosterone cypionate — the ester used in essentially every U.S. TRT clinic — is conjugated to a cyclopentylpropionate group that slows release from the depot. Studies estimate its half-life at approximately 8 days, with practical clinical observation suggesting 7-9 days depending on patient body composition, dose, and route of administration ^[1].

That half-life dictates everything that follows.

If a patient injects 140mg of testosterone cypionate intramuscularly once a week, here's roughly what happens to serum testosterone across that week:

• Day 1: Serum rises sharply — typically to 1,100-1,500 ng/dL, well above the optimal upper bound.
• Day 2-3: Levels remain elevated, often still 30-50% above optimal mid-range.
• Day 4-5: Plateau begins as the ester depot releases at a slower rate; serum drops into the optimal band.
• Day 6-7: Serum continues falling — for many patients into the low-to-borderline range — until the next injection.

The result is a sawtooth curve. Peak day 1-2. Trough day 6-7. Across that single week, the patient experiences his own testosterone like a stock chart in a volatile market.

Figure 1

Serum testosterone across one week — schematic comparison

Schematic representation based on testosterone cypionate pharmacokinetics in adult men ^[1][2]. Individual curves vary with dose, body composition, SHBG, and ester clearance. Reference range per LabCorp 2026 standard.

What ”crash and crawl” feels like

Patients describe the weekly cycle in remarkably consistent language. The taxonomy looks something like this:

• Day 1 (injection day): Tired-flat. Most patients haven't felt the new dose yet.
• Days 2-3: Spike. Energy elevated. Sleep deeper. Libido and morning physiology return. Patients often describe this as ”this is what I'm paying for.”
• Days 4-5: Plateau. Stable. The protocol ”works.” Patients schedule big workouts here.
• Days 6-7: Crash. Energy dips. Mood blurs. Sleep gets fragmented. Libido fades. Patients describe themselves as ”off.” Most schedule the next injection here.

Compounded across a year, that's roughly three months of ”great” stacked against three months of ”off” — even though the prescription label says he's been ”on TRT” the entire time.

This is not a marginal patient-experience issue. It's the central failure mode of weekly intramuscular protocols. And it's the reason daily subcutaneous dosing — published as superior in the endocrine literature for nearly a decade — should already be the default.

The literature, and the inertia

Spratt et al. (2017) published in Journal of Clinical Endocrinology & Metabolism the foundational comparison: subcutaneous testosterone injection produces pharmacokinetics that are not just non-inferior to intramuscular injection — they are preferred by patients on every measured axis (pain, convenience, serum stability) ^[1]. Subsequent studies in cisgender male hypogonadism populations have replicated the finding ^[2][3].

So why is your local TRT clinic still handing you a 30mL multi-dose vial and a 25-gauge intramuscular needle?

Three reasons, none of them clinical:

1. Supply chain. Compounding pharmacies have stocked vial-based testosterone for decades. Auto-injector pens are a newer category, developed primarily for the GLP-1 agonist market (Ozempic, Wegovy). The infrastructure to deliver testosterone via pen — at scale, at FDA-approved doses, with reliable batch consistency — only became commercially viable in the last 2-3 years.
2. Provider habit. Most prescribers learned weekly IM dosing during residency. Switching a clinic's default protocol requires retraining, updating standing orders, renegotiating pharmacy contracts. Most clinics don't bother.
3. The patient doesn't know what he doesn't know. If you've never experienced a flat serum curve, you don't realize the crash isn't a feature of TRT. It's a feature of the delivery method.

What makes daily practical

Here's where the conversation usually breaks down. Most TRT patients hear ”daily subcutaneous” and immediately picture filling a syringe every morning, locating an injection site, swabbing, jabbing, and cleaning up — every single day, for the rest of their lives.

That logistical friction is real. And historically, it's why daily subq stayed an academic preference rather than a clinical default.

The breakthrough is the auto-injector pen.

TruWell's parent operator built and ships the Apex auto-injector pen — a daily-dose subcutaneous delivery system that:

• Uses a half-inch subcutaneous needle (not 1.5-inch IM)
• Delivers a pre-set dose with a single click — typically 0.1-0.3 mL
• Takes 10 seconds, start to finish
• Ships to the patient's door in pre-filled cartridges from a LegitScript-certified, NABP-accredited compounding pharmacy upon TruWell provider authorization

The pen is the unlock. Without it, daily subq is a theoretical preference. With it, daily subq is what every TruWell patient on the All-In Bundle actually does — for $140/month, including the pen, the cartridges, the quarterly 23-biomarker labs, and the licensed nurse practitioner reviewing every panel.

If you're already on weekly: how to switch

Most patients who switch to daily subq go through a remarkably mechanical transition:

1. Calculate the daily dose. Take your current weekly dose, divide by 7. A patient on 140mg weekly intramuscular transitions to 20mg daily subcutaneous. The total weekly dose is preserved; only the cadence changes.
2. No washout, no taper. Daily dosing begins immediately. Because cypionate has an 8-day half-life, the existing depot is still releasing while the new daily protocol layers on top. Serum is continuously buffered.
3. Re-test labs at day 90. The provider compares baseline (last weekly-protocol labs) to the new 90-day daily-protocol labs. Adjustments to total dose, estradiol management, and ancillaries are made from the new data, not from extrapolation.
4. Expect ”every day feels like the same day” by week 2-3. The serum curve flattens within a few half-life cycles. Most patients describe the change as ”I didn't realize how much the crash was costing me until it stopped.”

What this means for your protocol

If you're a TRT patient currently on weekly intramuscular and your symptoms cycle across the week — energy spikes, libido dips, mood softens by Friday — the protocol is the problem, not your body, your age, or your dose.

If you're considering TRT for the first time, daily subcutaneous via auto-injector pen is the clinical default that the literature has supported for 8 years. There's no clinical reason to start on weekly intramuscular except that your prescriber learned it during residency.

The math is the math. The pen is what makes the math practical.